Abstract
Background: Treatment of advanced PCa remains a therapeutic challenge. Moreover, new immunotherapies like immune-checkpoint blockade (ICB) have shown significant benefits in only a minority of patients. CDK12 defect-PCa is a recently discovered molecular subtype of this tumor with a high neoantigen load and increased immune cell infiltrate. CDK12 defective PCa has variable results with re…